Monday, September 23, 2013

CYP2D6 genotype and tamoxifen response: meta-analysis of heterogeneous population

›
Tamoxifen treatment results in substantial inter-individual variability of outcome, possibly due to genetic variability in CYP2D6. ...
Tuesday, September 17, 2013

New EGFR VIP Summary Published in PG&G

›
The epidermal growth factor receptor ( EGFR ) is involved in the growth of many epithelial malignancies, such as non-small-cell lung cancer ...
Thursday, September 5, 2013

CPIC publishes guidelines for DPYD and fluoropyrimidines

›
The Clinical Pharmacogenetics Implementation Consortium ( CPIC ) has published guidelines for the use of genetic test results for DPYD in f...
Tuesday, September 3, 2013

Tamoxifen Pharmacokinetic Pathway Published

›
Tamoxifen , a selective estrogen receptor modulator, is used in the treatment and prevention of estrogen receptor positive breast cancer. Th...
Sunday, August 25, 2013

CYP2C8 VIP published in PG&G

›
CYP2C8 is a member of the cytochrome P450 family of drug metabolizing enzymes. It plays a major role in the metabolism of many commonly us...
Wednesday, August 21, 2013

New PharmGKB VIP Summary: NAT2

›
N -acetyltransferase enzymes (NAT1 and NAT2) are involved in the metabolism and detoxification of xenobiotics. NAT2 is predominantly express...
Monday, August 19, 2013

Tacrolimus and cyclosporine pathways published

›
Tacrolimus and cyclosporine are two immunosuppressants given to solid organ transplant patients to prevent allograft rejection. A PharmGKB s...